Incyte_DECK_JPM_2026_2026_01_12_FINAL.pdf

《Incyte_DECK_JPM_2026_2026_01_12_FINAL.pdf》由会员分享，可在线阅读，更多相关《Incyte_DECK_JPM_2026_2026_01_12_FINAL.pdf（28页珍藏版）》请在三个皮匠报告上搜索。

1、JP Morgan Healthcare ConferenceJANUARY 2026Forward looking statementsExcept for the historical information set forth herein,the matters set forth in this presentation contain predictions,estimates and other forward-looking statements,including without limitation statements regarding the following:tr

2、ansitioning Incyte to a high-growth,high-value Hem-Onc-IAI company;the potential for durable,scalable growth and value offered by Incytes assets and pipeline;outlook for 2026 and beyond,including expectations regarding pivotal trials,data readouts and product launches;Incytes target profile for 2029

3、 and beyond;guidance for Jakafi and Opzelura and expected growth drivers;tripling core business(ex-Jakafi)revenue by 2030;anticipated timing of pre-clinical development,clinical trials and regulatory submissions;anticipated next steps and milestones for 989,890,734 and povorcitinib,among other pipel

4、ine assets,and the potential presented by same;strategies for capital allocation,including plans to leverage business development;and expectations regarding 2026 catalysts and newsflow items.These forward-looking statements are based on Incytes current expectations and subject to risks and uncertain

5、ties that may cause actual results to differ materially,including unanticipated developments in and risks related to:future research and development,including the possibility that clinical trials will be unsuccessful or otherwise fail to meet applicable regulatory standards and/or warrant continued

6、development;the ability to enroll sufficient numbers of subjects in clinical trials,including the ability to enroll subjects in accordance with planned schedules;timing and initiation of clinical trials;determinations made by FDA and other regulatory agencies;Incytes relationships with its collabora